ECSP003681A - Polymorphic salt - Google Patents

Polymorphic salt

Info

Publication number
ECSP003681A
ECSP003681A ECSP003681A ECSP003681A EC SP003681 A ECSP003681 A EC SP003681A EC SP003681 A ECSP003681 A EC SP003681A EC SP003681 A ECSP003681 A EC SP003681A
Authority
EC
Ecuador
Prior art keywords
polymorphic salt
migraine
prescribed
medicine
graph
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Ronald James Ogilvie
Arthur Bentley
Simon Arnold Howard-Fielo
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP003681A publication Critical patent/ECSP003681A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El presente invento trata de una forma polimórfica cristalina de un compuesto de fórmula (I) (gráfico), caracterizada por un diagrama de difracción de rayos X en polvo, obtenido al utilizar la radiación K-alfa del cobre(f = 0,15046 nm), que presenta picos principales a 9,28, 10,38, 11,37, 12,40, 16,84, 17,46, 17,53, 17,78, 17,98, 19,48, 20,70, 21,29, 21,45, 22,21, 22,64, 23,08, 25,20, y 25,79. El invento se refiere también a procedimientos para la preparación de dicha forma, a composiciones farmacéuticas que contienen la misma y a su uso en medicina, particularmente en el tratamiento de estados para los que se prescribe un agonista de recptores 5-HT, tales como, por ejemplo, la migraña.The present invention deals with a crystalline polymorphic form of a compound of formula (I) (graph), characterized by a powder X-ray diffraction diagram, obtained by using the copper's K-alpha radiation (f = 0,15046 nm ), which presents major peaks at 9.28, 10.38, 11.37, 12.40, 16.84, 17.46, 17.53, 17.78, 17.98, 19.48, 20.70 , 21.29, 21.45, 22.21, 22.64, 23.08, 25.20, and 25.79. The invention also relates to processes for the preparation of said form, pharmaceutical compositions containing the same and their use in medicine, particularly in the treatment of conditions for which a 5-HT receptor agonist is prescribed, such as, by example, migraine.

ECSP003681 2000-09-25 2000-09-26 Polymorphic salt ECSP003681A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UY26354A UY26354A1 (en) 2000-09-25 2000-09-25 POLYMORPHIC SALT

Publications (1)

Publication Number Publication Date
ECSP003681A true ECSP003681A (en) 2002-04-23

Family

ID=38812230

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP003681 ECSP003681A (en) 2000-09-25 2000-09-26 Polymorphic salt

Country Status (2)

Country Link
EC (1) ECSP003681A (en)
UY (1) UY26354A1 (en)

Also Published As

Publication number Publication date
UY26354A1 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
HRP20160208T4 (en) Polymorphs of dasatinib and process for preparation thereof
AU2014306149B2 (en) KDM1A inhibitors for the treatment of disease
AR029570A1 (en) NEW GAMMA CRYSTAL FORM OF PERINDOPRIL TERBUTILAMINE SALT, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
CU23200A3 (en) Polymorphic salt
AR029571A1 (en) NEW BETA CRYSTALLINE FORM OF PERINDOPRIL TERBUTILAMINE SALT, PROCEDURE FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
MX2021011811A (en) PROTACS THAT DEGRADE THE ESTROGEN RECEPTOR.
HU229358B1 (en) Farnesyl protein transferase inhibitors for treating arthropathies
AR053147A1 (en) CRYSTALINE FORM OF IVABRADINE CHLORHYDRATE, A PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
JO3178B1 (en) New crystalline form VI of agomelatine, a process for its preparation and pharmaceutical compositions containing it
AR066158A1 (en) CRYSTALINE PIRIDAZINE COMPOSITE, A METHOD FOR THEIR ELABORATION AND A COMPOSITION THAT UNDERSTANDS IT.
NO20063517L (en) New crystalline form v of agomelatine, process for its preparation and pharmaceutical compositions containing the
ES2614934T3 (en) New crystalline form III of agomelatine, its preparation process and pharmaceutical compositions containing it
RU2011139107A (en) SPECIFIC COMPOUNDS OF DIARYLHYDANTOIN AND DIARYLTHYOGOIDANTOIN
CL2004000918A1 (en) COMPOUNDS DERIVED FROM QUINUCLIDINA, ANTAGONISTS OF THE M3 MUSCARINIC RECEIVER; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND TO TREAT AN ANTI-INFLAMMATORY OR ALLERGIC CONDITION, IN PARTICULAR OF THE RESPIRATORY ROADS
TW200736198A (en) New crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
PE20030738A1 (en) SUCCINIC ACID SALTS OF 5,7,14-TRIAZATETRACICLO [10.3.1.02,11.04,9] -HEXADECA-2 (11), 3,5,7,9-PENTAENE AND PHARMACEUTICAL COMPOSITIONS OF THE SAME
UA84896C2 (en) Hydronopol derivatives as agonists on human orl1 receptors
AR029347A1 (en) ADENINE COMPOUND, ISOGNANINE COMPOUND AND 2,6-DITIOXANTINE AS A PRECURSOR OF THE SAME, USE OF SUCH COMPOUNDS TO PREPARE A PHARMACEUTICAL COMPOSITION AND SUCH PHARMACEUTICAL COMPOSITION
MX376307B (en) OXAZETIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE IN HUMAN MEDICINE AND COSMETICS.
ECSP003681A (en) Polymorphic salt
AR053678A1 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS, THEIR MANUFACTURE, COMPOSITIONS THAT CONTAIN THEM AND THEIR USE
PE20131327A1 (en) DELTA CRYSTAL FORM OF PERINDOPRYL ARGININE SALT, ITS PREPARATION PROCEDURE, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
AR029458A1 (en) ACTIVE COMPOUNDS IN THE GLUCOCORTICOID RECEIVER
PE20070456A1 (en) SALICILATE AND GENTIZATE OF THE COMPOUND 8- {4- [3- (5-FLUORO-1H-INDOL-3-IL) -PROPYL] -PIPERAZIN-1-IL} -2-METHYL-4H-BENZO [1,4] OXAZIN-3-ONA
Park et al. Synthesis of iodine‐123 labeled quercetin and catechin as radical seeking agents